Additionally, these designs incorporated molecular fragments that enhance the interactions identified in the molecular docking studies conducted with inhibitors of the Progesterone-activated transcription factor nuclear receptor, Estrogen-activated transcription factor nuclear receptor, and tyrosine protein kinase erbB-2 receptor, which are key targets in the progression of breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.